Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
AstraZeneca
Merck
Boehringer Ingelheim
Moodys

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR ZELBORAF


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Zelboraf

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01495988 ↗ Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Terminated Genentech, Inc. Phase 2 2013-08-01 This phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor cobimetinib; or, (2) SOC plus bevacizumab, an anti-VEGF antibody that suppresses new blood vessel formation and can stimulate the immune system. Previous clinical studies in melanoma have shown that bevacizumab may improve clinical benefit (progression free survival) if combined with ipilimumab or abraxane. Preclinical studies suggest that VEGF increase plays a role in resistance to BRAF inhibitors. This randomized study will ask whether the addition of bevacizumab to targeted therapy SOC in BRAF mutant melanoma can improve response rates and clinical benefit. Patients may have received no therapy for advanced disease or up to 2 prior therapies, excluding BRAF and MEK inhibitors.
NCT01495988 ↗ Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Terminated Melanoma Research Foundation Breakthrough Consortium Phase 2 2013-08-01 This phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor cobimetinib; or, (2) SOC plus bevacizumab, an anti-VEGF antibody that suppresses new blood vessel formation and can stimulate the immune system. Previous clinical studies in melanoma have shown that bevacizumab may improve clinical benefit (progression free survival) if combined with ipilimumab or abraxane. Preclinical studies suggest that VEGF increase plays a role in resistance to BRAF inhibitors. This randomized study will ask whether the addition of bevacizumab to targeted therapy SOC in BRAF mutant melanoma can improve response rates and clinical benefit. Patients may have received no therapy for advanced disease or up to 2 prior therapies, excluding BRAF and MEK inhibitors.
NCT01519323 ↗ BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Terminated Hoffmann-La Roche Phase 1 2013-01-01 This open-label, multicenter. single arm Phase I dose-escalation study with efficacy tail extension will evaluate the maximum tolerated dose/recommended dose, the safety and efficacy of vemurafenib (RO5185426) in pediatric participants (aged 12 through 17) with newly diagnosed or recurrent surgically incurable and unresectable Stage IIIC or Stage IV melanoma harboring BRAFV600 mutations. Participants will receive vemurafenib orally twice daily until disease progression or unacceptable toxicity occurs.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zelboraf

Condition Name

Condition Name for Zelboraf
Intervention Trials
Melanoma 8
Malignant Melanoma 7
Metastatic Melanoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zelboraf
Intervention Trials
Melanoma 29
Neoplasms 12
Colorectal Neoplasms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zelboraf

Trials by Country

Trials by Country for Zelboraf
Location Trials
United States 319
Italy 43
Spain 26
Germany 18
France 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zelboraf
Location Trials
Texas 18
California 16
New York 16
Massachusetts 14
Tennessee 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zelboraf

Clinical Trial Phase

Clinical Trial Phase for Zelboraf
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zelboraf
Clinical Trial Phase Trials
Completed 14
Active, not recruiting 11
Terminated 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zelboraf

Sponsor Name

Sponsor Name for Zelboraf
Sponsor Trials
Genentech, Inc. 11
Hoffmann-La Roche 10
National Cancer Institute (NCI) 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zelboraf
Sponsor Trials
Other 46
Industry 39
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Johnson and Johnson
Express Scripts
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.